BamSEC and AlphaSense Join Forces
Learn More

Inhibikase Therapeutics Inc.

NASDAQ: IKT    
Share price (10/27/25): $1.56    
Market cap (10/27/25): $116 million

Material Contracts Filter

EX-10.1
from 10-Q 3 pages Amendment No. 3 to the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan
12/34/56
EX-10.30
from 10-K 4 pages Inhibikase Therapeutics, Inc. Non-Qualified Stock Option Agreement
12/34/56
EX-10.29
from 10-K 37 pages Employment Agreement
12/34/56
EX-10.28
from 10-K 37 pages Employment Agreement
12/34/56
EX-10.27
from 10-K 6 pages Consulting Agreement
12/34/56
EX-10.5
from 8-K 6 pages Settlement Agreement
12/34/56
EX-10.4
from 8-K 5 pages Email Only [•], 2024 [Name] Re: Director Offer Letter [•], This Director Offer Letter Constitutes an Agreement (“Agreement”) Between You and Inhibikase Therapeutics, Inc. (“Company”) and Contains All of the Terms and Conditions Relating to Your Service to the Company as a Class [•] Member of Our Board of Directors (“Board”)
12/34/56
EX-10.3
from 8-K 9 pages Support Agreement
12/34/56
EX-10.2
from 8-K 23 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 47 pages Securities Purchase Agreement
12/34/56
EX-10.20
from S-1 5 pages Support Agreement
12/34/56
EX-10.19
from S-1 2 pages Form of Lock-Up Agreement
12/34/56
EX-10.3
from 8-K 10 pages To the Holder of January 2023 Common Stock Purchase Warrants Re: Inducement Offer to Exercise Existing Common Stock Purchase Warrants Dear Holder
12/34/56
EX-10.2
from 8-K 7 pages Placement Agency Agreement
12/34/56
EX-10.1
from 8-K 38 pages Securities Purchase Agreement
12/34/56
EX-10.19
from S-1/A 34 pages Securities Purchase Agreement
12/34/56
EX-10.19
from S-1/A 34 pages Securities Purchase Agreement
12/34/56
EX-10.18
from S-1 23 pages Inhibikase Therapeutics, Inc. Employment Agreement
12/34/56
EX-10.1
from 8-K 44 pages At the Market Offering Agreement February 1, 2024
12/34/56
EX-10.3
from 8-K 29 pages Registration Rights Agreement
12/34/56